Proton Pump

Related Products

Proton pump is an integral membrane protein that is capable of moving protons across a biological membrane. Mechanisms are based on conformational changes of the protein structure or on theQ cycle. In cell respiration, the proton pump uses energy to transport protons from the matrix of the mitochondrion to the inter-membrane space. It is an active pump, that generates a protonconcentration gradient across the inner mitochondrial membrane, because there are more protons outside the matrix than inside. The difference in pH and electric charge (ignoring differences inbuffer capacity) creates an electrochemical potential difference that works similar to that of a battery or energy storing unit for the cell. The process could also be seen as analogous to cycling uphill or charging a battery for later use, as it produces potential energy. The proton pump does not create energy, but forms a gradient that stores energy for later use.

Proton Pump Related Products (164)
Antibodies (1)

By Effects:	Controls (3) Inhibitors (140) Agonists (3) Antagonists (3) Activators (2)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-13662S

Lansoprazole-d₄	Inhibitor	99.82%
Lansoprazole-d₄ is a deuterium labeled Lansoprazole. Lansoprazole is a proton pump inhibitor which prevents the stomach from producing acid.

HY-19223

Pumaprazole	Antagonist	99.75%
Pumaprazole is a reversible proton pump antagonist.

HY-13662BS

(R)-Lansoprazole-d₄	Inhibitor	99.13%
(R)-Lansoprazole-d₄ is deuterium labeled (R)-Lansoprazole. (R)-Lansoprazole is the R enantiomer of Lansoprazole, Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor).

HY-13662C

(S)-Lansoprazole	Inhibitor	99.17%
(S)-Lansoprazole (Levolansoprazole) is an isoform of Lansoprazole (HY-13662), which is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor).

HY-N6738

Bafilomycin B1		98.22%
Bafilomycin B1 is a macrolide antibiotic that can be isolated from mycelium of Streptomyces gresuis. Bafilomycin B1 is neuroprotective against Chloroquine (HY-17589A)-induced death. Bafilomycin B1 is a structural analog of Bafilomycin A1 and has the ability to inhibit V-ATPase. Bafilomycin B1 inhibits significantly the oxidized low density lipoprotein (LDL)-induced accumulation of lipid droplets.

HY-117025

Manzamine A	Inhibitor	98.2%
Manzamine A, an orally active beta-carboline alkaloid, inhibits specifically GSK-3β and CDK-5 with IC₅₀s of 10.2 μM and 1.5 μM, respectively. Manzamine A targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A has antimalarial and anticancer activities. Manzamine A also shows potent activity against HSV-1.

HY-W008614

Lansoprazole sulfone	Inhibitor	99.52%
Lansoprazole sulfone (AG-1813) is an orally active and selective inhibitor of H⁺, K⁺-ATPase. Lansoprazole sulfone can significantly stimulates gastric acid secretion by inhibiting H⁺, K⁺-ATPase. Lansoprazole sulfone has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease.

HY-P5421

Caloxin 1B1	Inhibitor	98.77%
Caloxin 1B1 is a biological active peptide. (Caloxin 1b1 is obtained by screening for binding to extracellular domain 1 of PMCA4, which inhibited PMCA extracellularly, selectively, and had a higher affinity for PMCA4 than PMCA1. Because caloxin 1b1 had been selected to bind to an extracellular domain of PMCA, it could be added directly to cells and tissues to examine its effects on smooth muscle and endothelium.)

HY-13100

PF 03716556	Antagonist	99.10%
PF 03716556 is a potent, selective, competitive and reversible acid pump (H⁺,K⁺-ATPase) antagonist with pIC₅₀s of 6.026, 6.038 and 6.009 for porcine, canine, and human recombinant gastric H⁺,K⁺-ATPase, respectively. PF 03716556 is inactive against other receptors, ion channels, and enzymes. PF 03716556 has the potential for gastroesophageal reflux disease research.

HY-17021B

Esomeprazole potassium salt	Inhibitor	98.18%
Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H⁺, K⁺-ATPase in gastric parietal cells. Esomeprazole potassium salt has the potential for symptomatic gastroesophageal reflux disease research.

HY-W016033

Pantoprazole sulfide	Control	98.83%
Pantoprazole sulfide is a metabolite of Pantoprazole (HY-17507), which is a proton-pump inhibitor.

HY-162935

V-ATPase-IN-1	Inhibitor	99.23%
V-ATPase-IN-1 (Compound 3b-03) is a Vacuolar-type H⁺-ATPases (V-ATPase) inhibitor (IC₅₀ = 194.80 μM) that can effectively target the V-ATPase subunit A (K_d = 0.803 μM). V-ATPase-IN-1 exhibits insecticidal activity against M. separata (LC₅₀ = 2.64 mM) and contributes to research in the development of chemical insecticides.

HY-109546

Omeprazole magnesium	Inhibitor
Omeprazole magnesium is an orally active proton pump inhibitor (PPI) and can suppress gastric acid. Omeprazole magnesium can be used for acid reflux-related symptoms and frequent heartburn research.

HY-17021C

Esomeprazole hemistrontium	Inhibitor
Esomeprazole ((S)-Omeprazole) hemistrontium is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H⁺, K⁺-ATPase in gastric parietal cells. Esomeprazole hemistrontium has the potential for symptomatic gastroesophageal reflux disease research.

HY-121851

Revaprazan	Inhibitor
Revaprazan (SB 641257) is a reversible proton pump inhibitor with significant anti-inflammatory effects. Revaprazan can be used for chronic gastric inflammation research.

HY-17623D

Tegoprazan Benzoate
Tegoprazan Benzoate is the benzoate form of Tegoprazan (HY-17623). Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a potent, oral active and highly selective inhibitor of gastric H⁺/K⁺-ATPase that could control gastric acid secretion and motility, with IC₅₀ values ranging from 0.29-0.52 μM for porcine, canine, and human H⁺/K⁺-ATPases in vitro.

HY-100007A

Vonoprazan hydrochloride	Inhibitor
Vonoprazan hydrochloride, a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan hydrochloride inhibits H⁺,K⁺-ATPase activity in porcine gastric microsomes with an IC₅₀ of 19 nM at pH 6.5. Vonoprazan hydrochloride is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan hydrochloride can be used for eradication of Helicobacter pylori.

HY-100412A

Linaprazan mesylate	Inhibitor
Linaprazan mesylate can inhibit H+,K+ -ATPase in the stomach through K+ competitive binding. (IC 50: 1.0 ± 0.2 μM), it has a strong inhibitory effect on acid. Linaprazan (AZD0865) mesylate can be used for research on reflux esophagitis with oral activity.

HY-17507CS

(R)-(+)-Pantoprazole-d₆
(R)-(+)-Pantoprazole-d₆ is deuterium labeled (R)-(+)-Pantoprazole.

HY-17507S

Pantoprazole-d₆	Inhibitor
Pantoprazole-d₆ is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI). Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142).

Name
Email *

	Sorry, but the email address you supplied was invalid.

Proton Pump

Proton Pump

Proton Pump Related Products (164)

Antibodies (1)

Proton Pump Related Products (164):